Agilent Technologies (A) Given Consensus Rating of “Buy” by Brokerages

Agilent Technologies (NYSE:A) has earned a consensus rating of “Buy” from the sixteen research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $72.52.

Several equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a research report on Wednesday, April 4th. ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Morgan Stanley lowered their price target on shares of Agilent Technologies from $95.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday, April 11th. Goldman Sachs upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating in a research report on Monday, April 9th. Finally, Robert W. Baird reissued a “buy” rating and set a $76.00 price objective on shares of Agilent Technologies in a research note on Thursday, January 18th.

How to Become a New Pot Stock Millionaire

A traded down $0.82 during midday trading on Thursday, hitting $68.73. The company had a trading volume of 333,180 shares, compared to its average volume of 2,467,352. The company has a current ratio of 3.23, a quick ratio of 2.78 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $22,070.26, a PE ratio of 29.30, a PEG ratio of 2.35 and a beta of 1.31. Agilent Technologies has a twelve month low of $52.79 and a twelve month high of $75.00.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.08. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. During the same quarter last year, the company posted $0.53 EPS. research analysts predict that Agilent Technologies will post 2.71 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 25th. Shareholders of record on Tuesday, April 3rd will be paid a $0.149 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, April 2nd. Agilent Technologies’s payout ratio is currently 25.42%.

In other news, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,638,750.00. Following the sale, the chief executive officer now owns 324,687 shares of the company’s stock, valued at $24,351,525. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 6,825 shares of the business’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $71.23, for a total transaction of $486,144.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,550 shares of company stock worth $3,225,202.

Several hedge funds have recently made changes to their positions in A. BlackRock Inc. lifted its position in shares of Agilent Technologies by 8.1% in the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after purchasing an additional 1,912,186 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Agilent Technologies by 325.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after buying an additional 1,812,500 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Agilent Technologies by 145.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after buying an additional 1,023,099 shares during the last quarter. Bank of Montreal Can increased its holdings in Agilent Technologies by 187.3% during the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after buying an additional 483,721 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Agilent Technologies by 21.5% during the fourth quarter. Millennium Management LLC now owns 2,550,899 shares of the medical research company’s stock worth $170,834,000 after buying an additional 450,925 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://weekherald.com/2018/04/26/agilent-technologies-a-given-consensus-rating-of-buy-by-brokerages.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply